Adial Pharmaceuticals, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Adial Pharmaceuticals, Inc. (ADIL) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net of -$4.68 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet · last filed 2026-08-14
- 2026-06-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net -$4.68M.
- 2022-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $594.04K.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|---|---|
| 2026-06-30 | -$4.68M 10-Q · filed 2026-08-14 |
| 2022-12-31 | $594.04K 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |